Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022
07 May 2022 - 6:05AM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the
“Company”) announces a change to the dial-in number(s) for the
upcoming first quarter financial and operational results
announcement on Tuesday, May 10, 2022. The new numbers for
interested participants to dial in are: (866) 682-6100 / (862)
298-0702 (Toll-free U.S. & Canada).
The audio webcast can also be accessed under "News/Events”
through the “Investors” section of the Aurinia corporate website at
www.auriniapharma.com. A replay of the webcast will be available on
Aurinia’s website.
About Aurinia
Aurinia is a fully integrated biopharmaceutical company focused
on delivering therapies to treat targeted patient populations that
are impacted by serious diseases with a high unmet medical need. In
January 2021, the Company introduced the first FDA-approved oral
therapy indicated for the treatment of adult patients with active
lupus nephritis (LN). Aurinia’s head office is in Victoria, British
Columbia; its U.S. commercial hub is in Rockville, Maryland; and
the Company focuses development efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220506005474/en/
Investor and Corporate Contact Dana Lynch, IR &
Corporate Communications dlynch@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2024 to May 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From May 2023 to May 2024